A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib. - Matsumura, Yuki; Inomata, Sho; Yamaguchi, Hikaru; Mine, Hayato; Takagi, Hironori; Watanabe, Masayuki; Ozaki, Yuki; Yamaura, Takumi; Fukuhara, Mitsuro; Muto, Satoshi; Okabe, Naoyuki; Hasegawa, Takeo; et al. (Thoracic Cancer, 2021)